- Home
- PRQR vs EDIT Comparison
PRQR vs EDIT Comparison
Compare PRQR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | EDIT |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 233.3M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PRQR | EDIT |
|---|---|---|
| Price | $2.34 | $2.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $8.14 | $4.13 |
| AVG Volume (30 Days) | 348.1K | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $18,859,556.00 | ★ $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.07 | $0.91 |
| 52 Week High | $3.97 | $4.54 |
Technical Indicators
Market Signals| Indicator | PRQR | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 34.57 |
| Support Level | $2.10 | $2.33 |
| Resistance Level | $2.40 | $2.55 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 89.49 | 19.00 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.